• 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • Hahn EA Beaumont JL Pilkonis PA et al


    13. Hahn EA, Beaumont JL, Pilkonis PA, et al. The PROMIS satisfaction with social participation measures demonstrated responsiveness in diverse clinical pop-ulations. J Clin Epidemiol. 2016;73:135e141.
    14. Askew RL, Cook KF, Revicki DA, Cella D, Amtmann D. Evidence from diverse clinical populations supported clinical validity of PROMIS pain interference and pain behavior. J Clin Epidemiol. 2016;73:103e111.
    16. Yost KJ, Eton DT, Garcia SF, Cella D. Minimally important differences were estimated for six patient-reported outcomes measurement information system-cancer scales in advanced-stage cancer patients. J Clin Epidemiol. 2011;64:507e516.
    17. Husson O, Haak HR, Oranje WA, Mols F, Reemst PH, van de Poll-Franse LV. Health-related quality of life among thyroid cancer survivors: A systematic review. Clin Endocrinol (Oxf). 2011;75:544e554.
    18. Kletzien H, Macdonald CL, Orne J, et al. Comparison between patient-perceived voice changes and quantitative voice measures in the first postoperative year 
    after thyroidectomy: A secondary analysis of a randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2018;144:995e1003. 19. Meek P, Carding PN, Howard DH, Lennard TW. Voice change following thyroid and parathyroid surgery. J Voice. 2008;22:765e772. 20. Jones E, Speyer R, Kertscher B, Denman D, Swan K, Cordier R. Health-related quality of life and oropharyngeal dysphagia: A systematic review. Dysphagia. 2018;33:141e172.
    21. Krekeler BN, Wendt E, Macdonald C, et al. Patient-reported dysphagia after
    thyroidectomy: A qualitative study. JAMA Otolaryngol Head Neck Surg.
    22. Vicente DA, Solomon NP, Avital I, et al. Voice outcomes after
    total thyroidectomy, partial thyroidectomy, or non-neck surgery using
    23. Grande GE, Myers LB, Sutton SR. How do patients who Angeli’s Salt participate in cancer support groups differ from those who do not? Psychooncology. 2006;15:321e334. Accepted Manuscript
    Title: Clinical features of aflatoxin B1-exposed patients with liver cancer and the molecular mechanism of aflatoxin B1 on liver cancer cells
    Authors: Rui Zhou, Meizhen Liu, Xiaoliu Liang, Min Su, Rong Li
    Please cite this article as: Zhou R, Liu M, Liang X, Su M, Li R, Clinical features of aflatoxin B1-exposed Angeli’s Salt patients with liver cancer and the molecular mechanism of aflatoxin B1 on liver cancer cells, Environmental Toxicology and Pharmacology (2019),
    This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before region of elongation is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
    Clinical features of aflatoxin B1-exposed patients with liver cancer and the
    molecular mechanism of aflatoxin B1 on liver cancer cells
    a Department of Hepatobiliary Surgery, Guigang City People's Hospital, The Eighth Affiliated Hospital of Guangxi Medical University, Guigang 537100, Guangxi, PR
    b College of Pharmacy, Guangxi Medical University, Guangxi, Nanning 530021, PR China;
    c Key Laboratory of Tumour Immunology and Microenvironmental Regulation, Guilin Medical University, Guangxi, Guilin 541004, PR China;
    1These authors share senior authorship
    Address correspondence to:
    · Increased AFB1 contents were found in blood and liver samples of HCC patients.
    · AKR7A was decreased in AFB1-exposed HCC patients.